Aclaris Therapeutics, Inc. (LON: 0H8T)

Market Cap	225.86M
Revenue (ttm)	20.20M
Net Income (ttm)	-27.61M
Shares Out	n/a
EPS (ttm)	-0.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29
Average Volume	5,434
Open	2.550
Previous Close	2.499
Day's Range	2.510 - 2.550
52-Week Range	0.605 - 10.870
Beta	n/a
RSI	41.73
Earnings Date	Feb 21, 2025

About Aclaris Therapeutics

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials f...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 89
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0H8T

Financial Performance

In 2023, Aclaris Therapeutics's revenue was $31.25 million, an increase of 5.03% compared to the previous year's $29.75 million. Losses were -$88.48 million, 1.81% more than in 2022.

Financial numbers in USD